SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

08 Nov 2023 Evaluate
The sales for the September 2023 quarter moved up 29.35% to Rs. 36592.30 millions as compared to Rs. 28289.60 millions during the corresponding quarter last year.The Total revenue for the quarter ended September 2023 of  Rs. 5486.10  millions  grew by 269.14% from Rs. 1486.20 millions.Operating profit for the quarter ended September 2023 rose to 8608.40 millions as compared to 3290.30 millions of corresponding quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 36592.30 28289.60 29.35 71548.70 55614.50 28.65 112588.30 117716.70 -4.36
Other Income 256.00 153.70 66.56 533.40 218.50 144.12 912.60 1504.20 -39.33
PBIDT 8608.40 3290.30 161.63 15936.00 6242.10 155.30 11739.20 4261.30 175.48
Interest 153.20 183.80 -16.65 315.00 382.50 -17.65 984.40 734.70 33.99
PBDT 8455.20 3106.50 172.18 15621.00 5859.60 166.59 10754.80 3526.60 204.96
Depreciation 1494.80 1377.60 8.51 2895.30 2681.10 7.99 5483.40 5141.90 6.64
PBT 6960.40 1728.90 302.59 12725.70 3178.50 300.37 5271.40 -1615.30 -426.34
TAX 1474.30 242.70 507.46 2470.00 520.50 374.54 1019.30 271.70 275.16
Deferred Tax 177.70 -45.00 -494.89 166.20 -56.60 -393.64 60.40 -306.30 -119.72
PAT 5486.10 1486.20 269.14 10255.70 2658.00 285.84 4252.10 -1887.00 -325.34
Equity 910.50 909.40 0.12 910.50 909.40 0.12 910.00 909.00 0.11
PBIDTM(%) 23.53 11.63 102.27 22.27 11.22 98.44 10.43 3.62 188.03

Lupin Share Price

2398.20 -21.95 (-0.91%)
01-Jul-2026 14:27 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1870.60
Dr. Reddys Labs. 1343.65
Cipla 1457.80
Zydus Lifesciences 1108.00
Lupin 2398.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: